The purpose of this study is to evaluate the efficacy and safety of generic entecavir monotherapy or in combination with adefovir for chronic hepatitis B patients with inadequate response to NUC therapy
Name: Entecavir
Description: patients will receive oral entecavir 1mg, daily for 104 weeks.Type: DrugA
Name: Entecavir, Adefovir
Description: patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeksType: DrugB
Name: Entecavir, Adefovir
Description: patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeksType: DrugC
Allocation: Randomized
Parallel Assignment
There is one SNP
The proportion of subjects with mutations of rtN236T/A181V, rtL180M/rtM204V/rtT184/rtS202 and/or rtM250 at week 104. --- A181V ---